← Back to Clinical Trials
Recruiting NCT07620223

NCT07620223 Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07620223
Status Recruiting
Phase
Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Condition Hepatobiliary Surgery
Study Type INTERVENTIONAL
Enrollment 378 participants
Start Date 2026-05-24
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Piperacillin-tazobactam

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 378 participants in total. It began in 2026-05-24 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To analyse the efficacy of different preoperative prophylactic antimicrobial regimens for perioperative infection prevention in patients undergoing hepatobiliary surgery in a high antimicrobial resistance setting.

Eligibility Criteria

Inclusion Criteria: * Adult patients aged ≥18 years; * Deemed eligible for elective hepatobiliary surgery; * Demonstrated comprehension of the study nature and expressed willingness to comply with trial procedures; * Capable of providing written informed consent. Exclusion Criteria: * History of β-lactam allergy or hypersensitivity * Uncontrolled preoperative infection; * Current or recent (within the preceding month) systemic corticosteroid administration; * Severe hepatic or renal impairment; * Pregnancy or lactation; * Concurrent enrolment in another clinical trial; * Any other condition deemed by the investigator to render the patient unsuitable for study participation.

Contact & Investigator

Central Contact

Dayu Chen, Pharmacist in Charge, PharmD

✉ cdy_pharmacy@njglyy.com

📞 +86-025-83106666-60924

Frequently Asked Questions

Who can join the NCT07620223 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatobiliary Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07620223 currently recruiting?

Yes, NCT07620223 is actively recruiting participants. Contact the research team at cdy_pharmacy@njglyy.com for enrollment information.

Where is the NCT07620223 trial being conducted?

This trial is being conducted at Nanjing, China.

Who is sponsoring the NCT07620223 clinical trial?

NCT07620223 is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. The trial plans to enroll 378 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology